Indoco announces launch of Brinzolamide Ophthalmic Suspension 1% in U.S.
The product is developed and manufactured by Indoco Remedies for TEVA at its facility in Goa. The ANDA approved by the US Food and Drug Administration for Brinzolamide Ophthalmic Suspension 1%, is used to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. Brinzolamide Ophthalmic Suspension 1% works by decreasing the amount of fluid within the eye. The US market size of this product is $184 million, according to IQVIA data as of December, 2020. Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-gene...